Chimera Partners
VC Fund
London, United Kingdom
Chimera Partners is a VC fund in London focused on Software and Medical. Chimera Partners Limited is a principal investment firm.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 63%
Last updated:
For AI agents: llms.txt
Industries Chimera Partners invests in
SoftwareMedicalMedical DeviceMobileHardware
Stages Chimera Partners invests in
Series ASeries BSeedSeries CSeries D
Countries Chimera Partners invests in
United KingdomCanadaUnited States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Mark Jaffray
|
|||
Ben Gill
|
|||
Investment Focus
Industry
- Software 4 (50%)
- Medical 2 (25%)
- Medical Device 2 (25%)
- Mobile 1 (13%)
- Hardware 1 (13%)
Stage
- Series A 2 (25%)
- Series B 2 (25%)
- Seed 1 (13%)
- Series C 1 (13%)
- Series D 1 (13%)
Country
- United Kingdom 3 (38%)
- Canada 1 (13%)
- United States 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Mark Jaffray
Partner
|
Partner | Total investments: 2 | Find email | |
|
Ben Gill
Partner
|
Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Shoplazza
|
Shoplazza is an award-winning shopping cart commerce technology company that provides differentiated value by offering technology that is easy to start, market and manage online stores of any size. The single integrated back-end platform powered by advanced data analytical capability is engineered for reliability, security and adaptivity, ensuringour merchants never miss a turn.Shoplazza champions merchants to not only build an online store but own their brand. The North America-based Direct-to-customer (“DTC”) branding incubation team provides service covering the entire journey of buyers that helps merchants develop a direct relationship with the buyers and make their brand memorable and distinctive.The company was founded in 2017 and with our global strategy department headquartered in Toronto. | $150M / Series C / Jan 20, 2022 | |
CMR Surgical
|
CMR Surgical develops and manufactures robotic surgical systems designed to enhance precision and efficiency in minimally invasive surgery. Its primary product, Versius, is a versatile and modular robotic system that supports various surgical procedures.Versius is designed to mimic the human arm's flexibility while offering a compact andergonomic design. It integrates with hospital workflows and provides data-driven insights to support surgical performance. CMR Surgical collaborates with healthcare professionals to ensure that its technology meets clinical needs and improves patient outcomes. | $600M / Series D / Jun 28, 2021 | |
Brainomix
|
Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $9.2M / Apr 03, 2018 | |
|
Brainomix
|
Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $2M / Series B / Oct 17, 2016 | |
GoReport
|
GoReport provides a range of purpose-built solutions for a variety of survey types across the entire property sector. Surveyors can now carry out surveys and generate reports more efficiently and in much less time. Surveyors can now quickly capture all relevant survey data directly on an iPad using a simple and easy to use combination of standardand custom phrases, automated voice to text and pick lists.GoReport was founded on 2011 and is headquartered in Belfast, United Kingdom. | $458K / Seed / Oct 01, 2016 | |
Fuel3D
|
Fuel3D is an affordable handheld 3D scanning system that delivers extremely high quality 3D shape and color capture for a range of creative applications. The Fuel3D handheld scanner is a point-and-shoot 3D scanning system that captures extremely high resolution mesh and color information of objects. Fuel3D is the world’s first 3D scanner to combinepre-calibrated stereo cameras with photometric imaging to capture and process files in seconds.But generating high quality 3D images for use in 3D printing or gaming is typically time-consuming and expensive. A handheld 3D scanner today can cost upwards of $15,000, pricing them well above what most independent game developers, designers and artists can afford.Born in Oxford University, Fuel3D is developed by an expert team of hardware and software engineers and scientists. Originally developed for the medical imaging sector, Fuel3D’s technology is being adapted for the broader 3D market, with the goal of bringing the benefits of point-and-shoot 3D imaging to consumers and professionals alike. Originally developed by Professor Ron Daniel, Lecturer in Engineering Science at Oxford University, Fuel3D is today led by Stuart Mead, CEO, a veteran of several successful global technology ventures. | $6.5M / Series B / Nov 04, 2014 | |
|
Brainomix
|
Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $1.6M / Series A / Sep 24, 2014 | |
|
Fuel3D
|
Fuel3D is an affordable handheld 3D scanning system that delivers extremely high quality 3D shape and color capture for a range of creative applications. The Fuel3D handheld scanner is a point-and-shoot 3D scanning system that captures extremely high resolution mesh and color information of objects. Fuel3D is the world’s first 3D scanner to combinepre-calibrated stereo cameras with photometric imaging to capture and process files in seconds.But generating high quality 3D images for use in 3D printing or gaming is typically time-consuming and expensive. A handheld 3D scanner today can cost upwards of $15,000, pricing them well above what most independent game developers, designers and artists can afford.Born in Oxford University, Fuel3D is developed by an expert team of hardware and software engineers and scientists. Originally developed for the medical imaging sector, Fuel3D’s technology is being adapted for the broader 3D market, with the goal of bringing the benefits of point-and-shoot 3D imaging to consumers and professionals alike. Originally developed by Professor Ron Daniel, Lecturer in Engineering Science at Oxford University, Fuel3D is today led by Stuart Mead, CEO, a veteran of several successful global technology ventures. | $2.1M / Series A / Feb 13, 2014 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Hardware Investors
40,144 investors
Medical Investors
18,848 investors
Mobile Investors
12,672 investors
Medical Device Investors
11,047 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
FAQ
What does Chimera Partners invest in?
Chimera Partners invests primarily in Software, Medical and Medical Device startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Chimera Partners?
Public channels for Chimera Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Chimera Partners?
The team at Chimera Partners includes Mark Jaffray (Partner) and Ben Gill (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
